Peter L Saltonstall, president and CEO of the US National Organization for Rare Disorders (NORD) shares the organization’s key priorities, what makes NORD a unique patient advocacy group in the US, prevailing access and affordability issues for American rare disease patients, and how the country should continue to incentivize a positive R&D environment for orphan drugs and rare diseases.
We really believe that data is a powerful tool that allows us to tell the stories of patients with rare diseases better
